Skip to search boxSkip to navigationSkip to main content

Modulation in the microRNA repertoire is responsible for the stage-specific effects of Akt suppression on murine neuroendocrine prostate cancer

  • Abdulrahman Alwhaibi
    ,
  • Fei Gao
    ,
  • Sandeep Artham
    ,
  • Bernard M. Hsia
    ,
  • Ashis Mondal
    ,
*Corresponding author for this work
  • University of Georgia
    ,
  • Chongqing Medical University
    ,
  • Augusta University
    ,
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Recent studies indicate a stage-specific, differential role for the oncogene Akt on various cancers. In prostate cancer (PCa), suppression of Akt activity in the advanced stages promoted transforming growth factor-β (TGFβ) pathway-mediated epithelial-to-mesenchymal transition (EMT) and metastasis to the lungs. In the current study, we performed Affymetrix analysis to compare the expression profile of microRNAs in the mouse prostate tissues collected at the prostatic inter-epithelial neoplasia (PIN) stage from Transgenic adenocarcinoma of the mouse (TRAMP)/Akt1+/+ versus TRAMP/Akt1–/– mice, and at the advanced stage from TRAMP/Akt1+/+ mice treated with triciribine (Akt inhibitor) versus DMSO-treated control. Our analysis demonstrates that in the early stage, Akt1 in the TRAMP prostate tumors express a set of miRNAs responsible for regulating cancer cell survival, proliferation, and tumor growth, whereas, in the advanced stages, a different set of miRNAs that promote EMT and cancer metastasis is expressed. Our study has identified novel Akt-regulated signature microRNAs in the early and advanced PCa and demonstrates their differential effects on PCa growth and metastasis.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Article number

e00796

Pages from-to (Number of pages)

Pages e00796

Journal (Volume, Issue Number)

Heliyon (Volume 4, Issue 9)

Publication milestones

  • Published - 09/2018

Publication status

Published - 09/2018

ISSN

2405-8440

Publication IDs

  • Scopus: 85053394231
  • ORCID: /0000-0002-8283-2403/work/66695206
  • PubMed: 30238065

Publication metrics

Metrics

SciVal
FWCI
0.13
SciVal
Author count
7
SciVal
citations
2
SciVal
Paper percentile
49
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
16
Social media
20
Citation count
8

Funding Details

This work was supported by the National Institutes of Health grants ( R01HL103952 and UL1TR002378 ). Payaningal R. Somanath was supported by the Wilson Pharmacy Foundation and Translational Research Initiative Grant . Abdulrahman Alwhaibi was supported by a fellowship provided by the King Saud University .